Syndax Pharmaceuticals annual depreciation and amortization
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Syndax Pharmaceuticals Depreciation & Amortization Growth & History (SNDX)
Syndax Pharmaceuticals's depreciation and amortization was $6.0M for fiscal 2025.
View full Syndax Pharmaceuticals company overviewSyndax Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.0M | −$2.0M | −25.00% |
| 2024 | 2024-12-31 | $8.0M | −$4.0M | −33.33% |
| 2023 | 2023-12-31 | $12.0M | −$21.0M | −63.64% |
| 2022 | 2022-12-31 | $33.0M | −$10.0M | −23.26% |
| 2021 | 2021-12-31 | $43.0M | $42.9M | +47677.78% |
| 2020 | 2020-12-31 | $90,000 | −$2,000 | −2.17% |
| 2019 | 2019-12-31 | $92,000 | $14,000 | +17.95% |
| 2018 | 2018-12-31 | $78,000 | $2,000 | +2.63% |
| 2017 | 2017-12-31 | $76,000 | −$13,000 | −14.61% |
| 2016 | 2016-12-31 | $89,000 | $68,000 | +323.81% |
| 2015 | 2015-12-31 | $21,000 | $6,000 | +40.00% |
| 2014 | 2014-12-31 | $15,000 | — | — |
Syndax Pharmaceuticals quarterly depreciation and amortization
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q1.17
Q2.17
Q3.17
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.0M | $5.0M | — |
| Q1 2026 | 2026-03-31 | $4.0M | $4.0M | — |
| Q4 2025 | 2025-12-31 | $3,000 | — | — |
| Q3 2025 | 2025-09-30 | $3,000 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q3 2017 | 2017-09-30 | $154,000 | — | — |
| Q2 2017 | 2017-06-30 | $73,000 | $69,000 | +1725.00% |
| Q1 2017 | 2017-03-31 | $6,000 | −$47,000 | −88.68% |
| Q2 2016 | 2016-06-30 | $4,000 | −$167,000 | −97.66% |
| Q1 2016 | 2016-03-31 | $53,000 | −$43,000 | −44.79% |
| Q3 2015 | 2015-09-30 | $190,000 | — | — |
| Q2 2015 | 2015-06-30 | $171,000 | — | — |
| Q1 2015 | 2015-03-31 | $96,000 | — | — |
Syndax Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Syndax Pharmaceuticals's depreciation and amortization increased from $90,000 to $6.0M, a change of $5.9M. The latest reported quarter, Q2 2026, shows $5.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Syndax Pharmaceuticals source filings ↗